Worth reading
41Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Finalization of issuance details for paid stock options and tax-qualified stock options
Who receives how much
2026 Series 1 Stock Acquisition Rights: 600,000 shares of the Company's common stock; 2026 Series 2 Stock Acquisition Rights: 592,900 shares of the Company's common stock
26 directors of the Company and its subsidiariesEquivalent to 600,000 shares (6,000 units)
502 employees of the Company and its subsidiariesEquivalent to 592,900 shares (5,929 units)
The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.
Terms of the stock acquisition rights
Exercise price
Series 2 Stock Acquisition Rights: ¥2,069 per share. Adjustment provisions and adjustment floor: Not disclosed. Series 1 Stock Acquisition Rights: Not disclosed
Number of Stock Acquisition Rights
Total number issued: Series 1, 6,000 units; Series 2, 5,929 units. Outstanding unexercised units: Not disclosed
Categories and Number of Persons Covered
26 directors of the Company and its subsidiaries (6,000 units); 502 employees of the Company and its subsidiaries (5,929 units)
Basis for determining the amount to be paid
The exercise price of the Series 2 Stock Acquisition Rights is equal to the closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on 24 March 2026 (¥2,069).
| Item | Details |
|---|---|
| Type of issuance or disposal | Finalization of issuance details for paid stock options and tax-qualified stock options |
| Number of shares to be issued or disposed of | 2026 Series 1 Stock Acquisition Rights: 600,000 shares of the Company's common stock; 2026 Series 2 Stock Acquisition Rights: 592,900 shares of the Company's common stock |
| Intended allottee | Name 26 directors of the Company and its subsidiaries / Number of Shares Equivalent to 600,000 shares (6,000 units), Name 502 employees of the Company and its subsidiaries / Number of Shares Equivalent to 592,900 shares (5,929 units) |
| Basis for determining the amount to be paid | The exercise price of the Series 2 Stock Acquisition Rights is equal to the closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on 24 March 2026 (¥2,069). |
| Exercise price | Series 2 Stock Acquisition Rights: ¥2,069 per share. Adjustment provisions and adjustment floor: Not disclosed. Series 1 Stock Acquisition Rights: Not disclosed |
| Number of Stock Acquisition Rights | Total number issued: Series 1, 6,000 units; Series 2, 5,929 units. Outstanding unexercised units: Not disclosed |
| Categories and Number of Persons Covered | 26 directors of the Company and its subsidiaries (6,000 units); 502 employees of the Company and its subsidiaries (5,929 units) |
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Certain previously undecided matters relating to the issuance announced on 27 February 2026 have been finalized.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.